See more : TEAM plc (TEAM.L) Income Statement Analysis – Financial Results
Complete financial analysis of Kyverna Therapeutics, Inc. (KYTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kyverna Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Tobii AB (publ) (TOBII.ST) Income Statement Analysis – Financial Results
- Hunting PLC (HNTIF) Income Statement Analysis – Financial Results
- Millennium Services Group Limited (MIL.AX) Income Statement Analysis – Financial Results
- Superior Industries International, Inc. (SUP) Income Statement Analysis – Financial Results
- Beijing Shiji Information Technology Co., Ltd. (002153.SZ) Income Statement Analysis – Financial Results
Kyverna Therapeutics, Inc. (KYTX)
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 7.03M | 5.66M |
| Cost of Revenue | 1.71M | 1.05M | 586.00K |
| Gross Profit | -1.71M | 5.97M | 5.07M |
| Gross Profit Ratio | 0.00% | 85.04% | 89.64% |
| Research & Development | 49.92M | 28.40M | 25.85M |
| General & Administrative | 12.48M | 8.01M | 6.15M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 12.48M | 8.01M | 6.15M |
| Other Expenses | 0.00 | -9.00K | -2.00K |
| Operating Expenses | 62.41M | 36.41M | 32.00M |
| Cost & Expenses | 62.41M | 36.41M | 32.00M |
| Interest Income | 2.28M | 565.00K | 1.00K |
| Interest Expense | 187.00K | 65.00K | 3.00K |
| Depreciation & Amortization | 1.71M | 1.05M | 586.00K |
| EBITDA | -58.47M | -27.78M | -25.76M |
| EBITDA Ratio | 0.00% | -395.40% | -455.46% |
| Operating Income | -62.41M | -29.38M | -26.35M |
| Operating Income Ratio | 0.00% | -418.28% | -465.81% |
| Total Other Income/Expenses | 2.04M | 491.00K | -4.00K |
| Income Before Tax | -60.37M | -28.89M | -26.35M |
| Income Before Tax Ratio | 0.00% | -411.29% | -465.88% |
| Income Tax Expense | 0.00 | 56.00K | 1.00K |
| Net Income | -60.37M | -28.89M | -26.35M |
| Net Income Ratio | 0.00% | -411.29% | -465.88% |
| EPS | 0.00 | -1.12 | -1.02 |
| EPS Diluted | 0.00 | -1.12 | -1.02 |
| Weighted Avg Shares Out | 673.62M | 25.80M | 25.80M |
| Weighted Avg Shares Out (Dil) | 673.62M | 25.80M | 25.80M |
The Schall Law Firm Encourages Shareholders To Participate In Kyverna Therapeutics Inc's Securities Fraud Investigation
The Schall Law Firm Invites Kyverna Therapeutics Inc's Investors To Join The KYTX Securities Fraud Investigation
The Schall Law Firm Encourages Kyverna Therapeutics Inc's Shareholders To Join The KYTX Securities Fraud Investigation
The Schall Law Firm Invites Kyverna Therapeutics Inc's Stakeholders To Participate In The KYTX Securities Fraud Investigation
Stakeholders Of Kyverna Therapeutics Inc Are Welcomed By The Schall Law Firm To Participate In The KYTX Securities Fraud Probe
Kyverna Therapeutics Inc's Stakeholders Are Invited By The Schall Law Firm To Join The KYTX Securities Fraud Investigation
Kyverna Therapeutics Inc's Stakeholders Are Invited By The Schall Law Firm To Join The KYTX Securities Fraud Investigation
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis
Kyverna Therapeutics Inc's Stakeholders Are Encouraged By The Schall Law Firm To Participate In The KYTX Securities Fraud Investigation
Source: https://incomestatements.info
Category: Stock Reports